Medivir announces initiation of the second cohort of the interferon-free phase II study combining Simeprevir and sofosbuvir for hepatitis C treatment
ET | Source:Medivir AB
Stockholm, Sweden—Medivir AB (OMX: MVIR), announced today the initiation of
cohort 2 in the interferon-free phase II trial combining simeprevir with
sofosbuvir (GS7977) based on a safety and efficacy planned interim analysis of
cohort 1 including prior null responder HCV genotype 1 infected patients without
advanced hepatic fibrosis. Data from the cohort 1 study will be presented at a
scientific conference during H1-2013.
Simeprevir, a NS3/4A protease inhibitor is being studied with sofosbuvir, a
nucleotide NS5B polymerase inhibitor, in a phase IIa, randomized, open-label
study to investigate the efficacy and safety of 12 or 24 weeks of simeprevir
(150 mg QD) and sofosbuvir (400 mg QD) with or without ribavirin (RBV) in HCV
genotype 1 (GT1) patients.
Cohort 1 included a total of 80 HCV GT1 prior null responders to PegIFN/RBV
therapy with METAVIR score F0-F2.
Cohort 2 (90 patients) will include both HCV GT1 treatment naïve and prior null
responders to PegIFN/RBV patients with advanced hepatic fibrosis (METAVIR score
F3 or F4). Patient screening for cohort 2 was recently initiated.
For more information please contact:
Rein Piir, EVP Corporate Affairs & IR Direct: +46 8 440 6550 or: Mobile: +46 708
About Simeprevir (TMC435)
Simeprevir is a once-daily potent investigational hepatitis C protease inhibitor
in late phase III clinical development being jointly developed by Medivir AB and
Janssen R&D Ireland to treat chronic hepatitis C virus infections. Simeprevir is
being investigated in combination with PegIFN/RBV in phase III trials and is
also being evaluated with direct-acting antiviral (DAA) agents in three other
phase II interferon free combinations both with and without ribavirin (RBV).
Global phase III studies of simeprevir include QUEST-1 and QUEST-2 in treatment
naïve patients, PROMISE in patients who have relapsed after prior IFN-based
treatment and ATTAIN in treatment experienced patients. In parallel to these
trials, phase III studies for simeprevir are ongoing in both treatment naïve and
treatment experienced HIV-HCV co-infected patients, HCV genotype 4 infected
patients and in Japanese HCV genotype 1 patients.
The phase II interferon-free combinations of simeprevir, include:
· Simeprevir in combination with Gilead Sciences’ sofosbuvir (GS7977) in
hepatitis C genotype 1 treatment-naïve or prior null responder patients.
· Simeprevir in combination with BMS’s, daclatasvir in hepatitis C genotype 1
treatment-naïve or prior null responder patients
· Simeprevir in combination with Janssen’s TMC647055 and low dose ritonavir in
hepatitis C genotype 1 treatment-naïve, prior relapser or null responder
· Simeprevir in combination with Vertex’s VX-135 in hepatitis C genotype 1
For additional information about Simeprevir please see www.clinicaltrials.gov
About Hepatitis C
Hepatitis C is a blood-borne infectious disease of the liver and is a leading
cause of chronic liver disease and liver transplants. The World Health
Organization estimates that nearly 170 million people worldwide, approximately
3% of the world's population, are infected with hepatitis C virus (HCV). The CDC
(Centers for Disease Control and Prevention) has reported that more than three
million people in the United States are chronically infected with HCV.
Medivir is an emerging research-based pharmaceutical company focused on
infectious diseases. Medivir has world class expertise in polymerase and
protease drug targets and drug development which has resulted in a strong
infectious disease R&D portfolio. The Company’s key pipeline asset is simeprevir
(TMC435), a novel protease inhibitor in phase III clinical development for
hepatitis C that is being developed in collaboration with Janssen R&D Ireland.
In June 2011, Medivir acquired the specialty pharmaceutical company BioPhausia
and today Medivir has a broad product portfolio with prescription
pharmaceuticals in the Nordics.
For more information about Medivir, please visit the Company’s website:
Medivir is a collaborative and agile pharmaceutical company with an R&D focus on
infectious diseases and a leading position in hepatitis C. We are passionate and
uncompromising in our mission to develop and commercialize innovative
pharmaceuticals that improve people’s lives.
GlobeNewswire, a Nasdaq company, is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
2321 Rosecrans Avenue.
El Segundo, CA 90245 Phone: (800) 307-6627 Fax: (800) 307-3567
25 Basinghall Street,
London EC2V 5HA
UK Phone: +1 866-465-8454